Literature DB >> 16482560

Hepatitis C virus genotype 3 predominates in North and Central India and is associated with significant histopathologic liver disease.

Syed S Hissar1, Ankur Goyal, Manoj Kumar, Chandana Pandey, P V Suneetha, Ajit Sood, Vandana Midha, Puja Sakhuja, Veena Malhotra, Shiv K Sarin.   

Abstract

Hepatitis C virus (HCV) genotypes help to tailor the treatment response, but their influence on the disease severity and association with hepatic steatosis is not well understood. The prevalence of HCV genotypes and their correlation with the histopathological severity of liver disease and steatosis in Indian patients were studied. HCV-RNA and genotyping was carried out in 398 patients with chronic hepatitis C. Liver biopsy was available in 292 (73.4%) patients. The severity of liver disease was graded on the basis of the histological activity index and the stage of hepatic fibrosis. The patients were categorized as having mild (histological activity index < or =5 and/or fibrosis < or =2) or severe (histological activity index > or =6 and/or fibrosis > or =3) liver disease. Steatosis was graded in 106 patients as 0 (no steatosis), 1 (<33% of hepatocytes affected), 2 (33%-66% of hepatocytes affected), or 3 (>66% of hepatocytes affected). HCV genotype 3 was detected in 80.2% patients (3a:24.4%, 3b:3.3%, 3c:0.5%, 3a/3b:36.7%, and un-subtypable 3:15.3%), genotype 1 in 13.1% (1a:3%, 1b:5.5%, 1a/1b:0.3%, and un-subtypable 1:4.3%), genotype 4 in 3% patients (4a:1.5%, 4b:0.3%, 4a/4c:0.5%, and un-subtypable 4:0.8%), 2 in 2.5% and mixed genotypes (more than one genotype) in 1.3% of patients. The median histological activity index and fibrosis scores were: 5 and 2 in genotype 1; 4 and 2 in genotype 2; 5 and 2 in genotype 3; 7 and 3 in genotype 4; and 5 and 2 in mixed genotypes, respectively. Severe liver disease was present in 17 of 38 (45%) with genotype 1; in 1 of 3 (33%) with genotype 2; in 128 of 236 (54%) with genotype 3; 7 of 10 (70%) with genotype 4; and in 1 of 4 (25%) with mixed genotype. Hepatic steatosis grade > or =2 was found in 28.1% of genotype 3; 23.5% of genotype 1; 20% of genotype 4; and in none of genotype 2 and mixed genotypes. In conclusion, genotype 3 is the most prevalent genotype in patients with chronic hepatitis C in North and Central India and this is associated with significant hepatic steatosis and fibrosis. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2006        PMID: 16482560     DOI: 10.1002/jmv.20561

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  31 in total

1.  Response of combination therapy on viral load and disease severity in chronic hepatitis C.

Authors:  Deepak Kumar; Abdul Malik; Mohammad Asim; Anita Chakravarti; Rakha H Das; Premashis Kar
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

Review 2.  Hepatitis C in India.

Authors:  Ashis Mukhopadhyaya
Journal:  J Biosci       Date:  2008-11       Impact factor: 1.826

3.  Comparison of 5' noncoding-core with 5' noncoding regions of HCV by RT-PCR: importance and clinical implications.

Authors:  Vikas Verma; Anita Chakravarti
Journal:  Curr Microbiol       Date:  2008-07-09       Impact factor: 2.188

4.  Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C.

Authors:  Pn Rao; Abraham Koshy; Jacob Philip; Narayanan Premaletha; Joy Varghese; Krishnasamy Narayanasamy; Samir Mohindra; Nitin Vikas Pai; Manoj Kumar Agarwal; Ashoknanda Konar; Hasmukh B Vora
Journal:  World J Hepatol       Date:  2014-07-27

5.  Early Experience of Sofosbuvir based Combination Therapy in "Real-Life" Cohort with Chronic Hepatitis-C Infection.

Authors:  Rajiv Mehta; Mayank Kabrawala; Subhash Nandwani; Rini Tekriwal; Payal Nandania
Journal:  J Clin Diagn Res       Date:  2017-03-01

Review 6.  Sequence diversity of hepatitis C virus: implications for immune control and therapy.

Authors:  Joerg Timm; Michael Roggendorf
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

7.  Diversity of Hepatitis C virus in Southern India Based on 5'UTR Sequence.

Authors:  R Amjesh; Achuthsankar S Nair; V S Sugunan
Journal:  Indian J Virol       Date:  2012-09-25

8.  Clinicopathological features and genotype distribution in patients with hepatitis C virus chronic liver disease.

Authors:  Rachel Abraham; Banumathi Ramakrishna; Avinash Balekuduru; Hubert Darius J Daniel; Priya Abraham; C Eapen Eapen; George Kurian
Journal:  Indian J Gastroenterol       Date:  2009-08-21

9.  Efficacy and safety of sofosbuvir-based therapy for chronic hepatitis C infection in "real-life" cohort.

Authors:  Rajiv Mehta; Mayank Kabrawala; Subhash Nandwani; Rini Tekriwal; Payal Nandaniya; Mrunal Shah; Vishwa Bhayani
Journal:  Indian J Gastroenterol       Date:  2016-11-08

10.  Prevalence of hepatitis C virus in aligarh: a seven year experience.

Authors:  Farhan Asif Siddiqui; Kafil Akhtar; Rana K Sherwani; Khaliqur Rehman; Feroz Alam; Athar Ansari
Journal:  Indian J Community Med       Date:  2009-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.